112 related articles for article (PubMed ID: 36814131)
21. [Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer].
Matveev VB; Kirichek AA; Safronova VM; Khafizov KO; Filippova MG; Lyubchenko LN
Urologiia; 2019 Sep; (4):51-57. PubMed ID: 31535805
[TBL] [Abstract][Full Text] [Related]
22. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
23. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
[TBL] [Abstract][Full Text] [Related]
24. Construction and validation of a fatty acid metabolism-related gene signature for predicting prognosis and therapeutic response in patients with prostate cancer.
Zhao H; Wu T; Luo Z; Huang Q; Zhu S; Li C; Zhang Z; Zhang J; Zeng J; Zhang Y
PeerJ; 2023; 11():e14854. PubMed ID: 36778142
[TBL] [Abstract][Full Text] [Related]
25. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
26. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
Front Immunol; 2022; 13():777724. PubMed ID: 35154101
[TBL] [Abstract][Full Text] [Related]
27. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
28. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
Front Immunol; 2022; 13():946209. PubMed ID: 36569837
[TBL] [Abstract][Full Text] [Related]
29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
30. PTEN Loss and PD-L1 Expression of Different Histological Patterns of Prostate Cancer.
Kir G; Cecikoglu GE; Olgun ZC; Kazan HO; Yildirim A
Pathol Res Pract; 2022 Jan; 229():153738. PubMed ID: 34922209
[TBL] [Abstract][Full Text] [Related]
31. The Complexity and Dynamics of the Tissue Glycoproteome Associated With Prostate Cancer Progression.
Kawahara R; Recuero S; Srougi M; Leite KRM; Thaysen-Andersen M; Palmisano G
Mol Cell Proteomics; 2021; 20():100026. PubMed ID: 33127837
[TBL] [Abstract][Full Text] [Related]
32. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
35. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
36. Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients.
Cai J; Chen Z; Chen X; Huang H; Lin X; Miao B
Biomed Res Int; 2020; 2020():4264291. PubMed ID: 32953881
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer.
Zhang G; Luo Y; Dong W; Zhong W
Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
[TBL] [Abstract][Full Text] [Related]
38. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
39. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
[TBL] [Abstract][Full Text] [Related]
40. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer.
Shao N; Tang H; Mi Y; Zhu Y; Wan F; Ye D
Oncoimmunology; 2020 Jun; 9(1):1762473. PubMed ID: 32923125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]